Drug intelligence / Profile preview

MGN-001

Development stage: Preclinical
Lead developer: MetaGen Biologics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

MGN-001 is a preclinical antibody-drug conjugate (ADC) being developed by MetaGen Biologics for the treatment of a wide range of solid and hematological malignancies. The drug is engineered using MetaGen's proprietary 3rdGO ADC engineering platform, which involves linking a specific antibody to a cytotoxic payload to deliver targeted therapy directly to cancer cells. MGN-001 is currently under investigation for multiple indications, including ovarian, cervical, prostate, pancreatic, lung, liver, brain, muscle, blood, colorectal, kidney, and head and neck cancers.

Beyond the preview

Go deeper on MGN-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGN-001.

Explore the full profile